Foghorn Therapeutics Inc. Operating Expenses
Foghorn Therapeutics Inc. (FHTX) reported Operating Expenses of $24.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Foghorn Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $24.88M, a 13.18% decline year-over-year.
- Foghorn Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $24.84M, a 13.94% decline year-over-year.
- Foghorn Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $33.13M, a 23.32% increase year-over-year.
- Foghorn Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $26.65M, a 15.81% decline year-over-year.
- Foghorn Therapeutics Inc. operating expenses for fiscal 2025 was $117.30M, a 6.38% decline from fiscal 2024.
- Foghorn Therapeutics Inc. operating expenses for fiscal 2024 was $125.28M, a 11.81% decline from fiscal 2023.
- Foghorn Therapeutics Inc. operating expenses for fiscal 2023 was $142.06M, a 4.18% increase from fiscal 2022.
- Foghorn Therapeutics Inc. operating expenses for fiscal 2022 was $136.37M, a 33.62% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.88M 10-Q · filed 2026-08-06 | $49.72M 10-Q · filed 2026-08-06 | $82.84M derived: sum of 3 quarters · filed 2026-08-06 | $109.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $24.84M 10-Q · filed 2026-05-07 | $57.97M derived: sum of 2 quarters · filed 2026-05-07 | $84.62M derived: sum of 3 quarters · filed 2026-05-07 | $113.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $33.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $59.78M derived: sum of 2 quarters · filed 2026-03-11 | $88.43M derived: sum of 3 quarters · filed 2026-08-06 | $117.30M 10-K · filed 2026-03-11 |
| 2025-09-30 | $26.65M 10-Q · filed 2025-11-05 | $55.31M derived: sum of 2 quarters · filed 2026-08-06 | $84.17M 10-Q · filed 2025-11-05 | $111.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $28.65M 10-Q · filed 2026-08-06 | $57.52M 10-Q · filed 2026-08-06 | $84.38M derived: sum of 3 quarters · filed 2026-08-06 | $116.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $28.86M 10-Q · filed 2026-05-07 | $55.73M derived: sum of 2 quarters · filed 2026-05-07 | $87.39M derived: sum of 3 quarters · filed 2026-05-07 | $120.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $26.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $58.52M derived: sum of 2 quarters · filed 2026-03-11 | $92.04M derived: sum of 3 quarters · filed 2026-03-11 | $125.28M 10-K · filed 2026-03-11 |
| 2024-09-30 | $31.66M 10-Q · filed 2025-11-05 | $65.18M derived: sum of 2 quarters · filed 2025-11-05 | $98.42M 10-Q · filed 2025-11-05 | $129.65M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $33.52M 10-Q · filed 2025-08-05 | $66.76M 10-Q · filed 2025-08-05 | $97.99M derived: sum of 3 quarters · filed 2025-08-05 | $132.55M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $33.24M 10-Q · filed 2025-05-14 | $64.47M derived: sum of 2 quarters · filed 2025-05-14 | $99.03M derived: sum of 3 quarters · filed 2025-05-14 | $136.68M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $31.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $65.79M derived: sum of 2 quarters · filed 2025-03-06 | $103.44M derived: sum of 3 quarters · filed 2025-03-06 | $142.06M 10-K · filed 2025-03-06 |
| 2023-09-30 | $34.56M 10-Q · filed 2024-11-04 | $72.21M derived: sum of 2 quarters · filed 2024-11-04 | $110.83M 10-Q · filed 2024-11-04 | $146.90M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $37.65M 10-Q · filed 2024-08-08 | $76.28M 10-Q · filed 2024-08-08 | $112.34M derived: sum of 3 quarters · filed 2024-08-08 | $147.24M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $38.63M 10-Q · filed 2024-05-06 | $74.70M derived: sum of 2 quarters · filed 2024-05-06 | $109.59M derived: sum of 3 quarters · filed 2024-05-06 | $143.27M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $36.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $70.96M derived: sum of 2 quarters · filed 2024-03-07 | $104.64M derived: sum of 3 quarters · filed 2024-03-07 | $136.37M 10-K · filed 2024-03-07 |
| 2022-09-30 | $34.89M 10-Q · filed 2023-11-02 | $68.57M derived: sum of 2 quarters · filed 2023-11-02 | $100.30M 10-Q · filed 2023-11-02 | $129.09M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $33.68M 10-Q · filed 2023-08-04 | $65.40M 10-Q · filed 2023-08-04 | $94.20M derived: sum of 3 quarters · filed 2023-08-04 | $120.50M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $31.72M 10-Q · filed 2023-05-08 | $60.52M derived: sum of 2 quarters · filed 2023-05-08 | $86.82M derived: sum of 3 quarters · filed 2023-05-08 | $110.36M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $28.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $55.10M derived: sum of 2 quarters · filed 2023-03-09 | $78.64M derived: sum of 3 quarters · filed 2023-03-09 | $102.05M 10-K · filed 2023-03-09 |
| 2021-09-30 | $26.30M 10-Q · filed 2022-11-08 | $49.84M derived: sum of 2 quarters · filed 2022-11-08 | $73.26M 10-Q · filed 2022-11-08 | $94.29M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $23.54M 10-Q · filed 2022-08-09 | $46.96M 10-Q · filed 2022-08-09 | $67.99M derived: sum of 3 quarters · filed 2022-08-09 | $86.65M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $23.42M 10-Q · filed 2022-05-09 | $44.45M derived: sum of 2 quarters · filed 2022-08-09 | $63.11M derived: sum of 3 quarters · filed 2022-08-09 | $78.65M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $21.03M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $39.70M derived: sum of 2 quarters · filed 2022-08-09 | $55.24M derived: sum of 3 quarters · filed 2022-08-09 | $68.96M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $18.67M 10-Q · filed 2021-11-09 | $34.21M derived: sum of 2 quarters · filed 2021-11-09 | $47.93M 10-Q · filed 2021-11-09 | $63.12M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $15.54M 10-Q · filed 2021-08-10 | $29.26M 10-Q · filed 2021-08-10 | $44.45M derived: sum of 3 quarters · filed 2021-08-10 | $57.55M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $13.72M 10-Q · filed 2021-05-11 | $28.91M derived: sum of 2 quarters · filed 2021-05-11 | $42.01M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $15.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $28.29M derived: sum of 2 quarters · filed 2021-03-18 | $51.08M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $13.10M 10-Q · filed 2020-12-04 | $35.90M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |